HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Irvine-based St. Joseph Health bought 26 Nurse Next Door franchises with an option to buy 12 more.
Genetic testing provider Ambry Genetics Corp. will open a new, 65,000-square-foot laboratory across the street from its Aliso Viejo headquarters this month.
HEALTHCARE: Aims to lead in central nervous system drugs
Aliso Viejo-based Avanir Pharmaceuticals Inc.’s newly appointed chief executive has what he calls a “very simplistic” vision for the drugmaker.
Buy of Digital Company Deepens Social Efforts
Irvine-based Alphaeon Corp. is continuing to grow its healthcare technology presence.
Irvine-based Edwards Lifesciences Corp. beat analyst expectations on quarterly revenue and profit and boosted full-year expectations in a report issued after markets closed Tuesday.
Aliso Viejo-based Avanir Pharmaceuticals Inc. said today that the Food and Drug Administration approved its Onzetra Xsail drug for treating adults’ acute migraine headache.
Irvine-based Quality Systems Inc. reported financial results that missed Wall Street expectations for the three months ended Dec. 31.
Children’s Hospital of Orange County will expand its neonatal intensive care unit.
Irvine-based St. Joseph Health said today that Kevin Manemann is the new chief executive of its St. Joseph Heritage Healthcare physician practice management organization.
Avanir Pharmaceuticals Inc., an Aliso Viejo-based drugmaker, named Rohan Palekar its chief executive.
Fear Possible Faith-Based Access Restrictions
Some advocacy groups are urging regulators not to waive a merger review of Irvine-based St. Joseph Health and Renton, Wash.-based Providence Health and Services’ proposed mega-affiliation.
University of California-Irvine today named Dr. Howard Federoff chief executive of UC Irvine Health.
Irvine-based Axonics Modulation Technologies Inc. raised $38.5 million in Series B financing.
Orange County entrepreneurs received more than $529 million in venture capital spread across 12 deals in the fourth quarter, said Dow Jones VentureSource.